Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Prostate Cancer

  Free Subscription

Articles published in Oncol Rep

Retrieve available abstracts of 84 articles:
HTML format

Single Articles

    September 2021
  1. DU W, Li D, Xie J, Tang P, et al
    miR3673p downregulates Rab23 expression and inhibits Hedgehog signaling resulting in the inhibition of the proliferation, migration, and invasion of prostate cancer cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available

    August 2021
  2. TORRES MJ, Lopez-Moncada F, Herrera D, Indo S, et al
    Endothelin-1 induces changes in the expression levels of steroidogenic enzymes and increases androgen receptor and testosterone production in the PC3 prostate cancer cell line.
    Oncol Rep. 2021;46.
    PubMed     Abstract available

    July 2021
  3. LI JM, Lee S, Zafar R, Shin E, et al
    Sodium bicarbonate transporter NBCe1 regulates proliferation and viability of human prostate cancer cells LNCaP and PC3.
    Oncol Rep. 2021;46.
    PubMed     Abstract available

    May 2021
  4. PEREZ G, Lopez-Moncada F, Indo S, Torres MJ, et al
    Knockdown of ZEB1 reverses cancer stem cell properties in prostate cancer cells.
    Oncol Rep. 2021;45.
    PubMed     Abstract available

    April 2021
  5. YANG Y, Liu T, Hu C, Xia H, et al
    Ferroptosis inducer erastin downregulates androgen receptor and its splice variants in castrationresistant prostate cancer.
    Oncol Rep. 2021;45:1.
    PubMed     Abstract available

    March 2021
  6. ZHU J, Qin P, Cao C, Dai G, et al
    Use of miR145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer.
    Oncol Rep. 2021;45:963-974.
    PubMed     Abstract available

  7. JI J, Shen T, Li Y, Liu Y, et al
    CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway.
    Oncol Rep. 2021;45:921-932.
    PubMed     Abstract available

    December 2020
  8. XIE H, Zhao J, Wan J, Zhao J, et al
    Long noncoding RNA AC245100.4 promotes prostate cancer tumorigenesis via the microRNA1455p/RBBP5 axis.
    Oncol Rep. 2020 Dec 10. doi: 10.3892/or.2020.7894.
    PubMed     Abstract available

    November 2020
  9. NOGUCHI M, Fujimoto K, Arai G, Uemura H, et al
    A randomized phase III trial of personalized peptide vaccination for castrationresistant prostate cancer progressing after docetaxel.
    Oncol Rep. 2020 Nov 11. doi: 10.3892/or.2020.7847.
    PubMed     Abstract available

  10. HE G, Li M, Fang L, Xu L, et al
    NMyc induces the tumor progression of prostate cancer by regulating FSCN1.
    Oncol Rep. 2020;44:2265-2274.
    PubMed     Abstract available

    October 2020
  11. SHIMIZU K, Matsumoto H, Hirata H, Ueno K, et al
    ARHGAP29 expression may be a novel prognostic factor of cell proliferation and invasion in prostate cancer.
    Oncol Rep. 2020 Oct 15. doi: 10.3892/or.2020.7811.
    PubMed     Abstract available

  12. XU X, Zhu Z, Xu Y, Tian S, et al
    Effects of zinc finger protein 403 on the proliferation, migration and invasion abilities of prostate cancer cells.
    Oncol Rep. 2020 Oct 1. doi: 10.3892/or.2020.7786.
    PubMed     Abstract available

    September 2020
  13. BAI S, Chen T, Yu X, Luo M, et al
    [Corrigendum] The specific killing effect of matrine on castrationresistant prostate cancer cells by targeting the Akt/FoxO3a signaling pathway.
    Oncol Rep. 2020 Sep 29. doi: 10.3892/or.2020.7784.
    PubMed     Abstract available

  14. HUO W, Qi F, Wang K
    Long noncoding RNA BCYRN1 promotes prostate cancer progression via elevation of HDAC11.
    Oncol Rep. 2020;44:1233-1245.
    PubMed     Abstract available

  15. WANG F, Wang W, Lu L, Xie Y, et al
    MicroRNA165p regulates cell survival, cell cycle and apoptosis by targeting AKT3 in prostate cancer cells.
    Oncol Rep. 2020;44:1282-1292.
    PubMed     Abstract available

    MDM2 as a target for ellagic acidmediated suppression of prostate cancer cells in vitro.
    Oncol Rep. 2020;44:1255-1265.
    PubMed     Abstract available

    August 2020
  17. WANG H, Huang W, Yu X, Li W, et al
    [Corrigendum] Two prostate cancerassociated polymorphisms in the 3'UTR of IGF1R influences prostate cancer susceptibility by affecting miRNA binding.
    Oncol Rep. 2020;44:786.
    PubMed     Abstract available

    July 2020
  18. LING XH, Fu H, Chen ZY, Lu JM, et al
    [Corrigendum] miR505 suppresses prostate cancer progression by targeting NRCAM.
    Oncol Rep. 2020 Jul 17. doi: 10.3892/or.2020.7696.
    PubMed     Abstract available

    June 2020
  19. WANG Y, Pei X, Xu P, Tan Z, et al
    E2F7, regulated by miR30c, inhibits apoptosis and promotes cell cycle of prostate cancer cells.
    Oncol Rep. 2020 Jun 24. doi: 10.3892/or.2020.7659.
    PubMed     Abstract available

    May 2020
  20. LIN M, Bu C, He Q, Gu J, et al
    TAZ is overexpressed in prostate cancers and regulates the proliferation, migration and apoptosis of prostate cancer PC3 cells.
    Oncol Rep. 2020 May 19. doi: 10.3892/or.2020.7616.
    PubMed     Abstract available

    February 2020
  21. JIANG G, Liang X, Huang Y, Lan Z, et al
    p62 promotes proliferation, apoptosisresistance and invasion of prostate cancer cells through the Keap1/Nrf2/ARE axis.
    Oncol Rep. 2020 Feb 28. doi: 10.3892/or.2020.7527.
    PubMed     Abstract available

  22. PU J, Li T, Liu N, Luo C, et al
    PLCepsilon knockdown enhances the radiosensitivity of castrationresistant prostate cancer via the AR/PARP1/DNAPKcs axis.
    Oncol Rep. 2020 Feb 26. doi: 10.3892/or.2020.7520.
    PubMed     Abstract available

    January 2020
  23. KASAJIMA R, Yamaguchi R, Shimizu E, Tamada Y, et al
    Variant analysis of prostate cancer in Japanese patients and a new attempt to predict related biological pathways.
    Oncol Rep. 2020 Jan 27. doi: 10.3892/or.2020.7481.
    PubMed     Abstract available

    December 2019
  24. LI W, Zhang J, Zou L, Cui J, et al
    Palmitoylome profiling indicates that androgens regulate the palmitoylation of alphatubulin in prostate cancerderived LNCaP cells and supernatants.
    Oncol Rep. 2019;42:2788-2796.
    PubMed     Abstract available

    November 2019
  25. QI JC, Xue WY, Zhang YP, Qu CB, et al
    Cholinergic alpha5 nicotinic receptor is involved in the proliferation and invasion of human prostate cancer cells.
    Oncol Rep. 2019 Nov 20. doi: 10.3892/or.2019.7411.
    PubMed     Abstract available

  26. HU R, Lu Z
    Long noncoding RNA HCP5 promotes prostate cancer cell proliferation by acting as the sponge of miR4656 to modulate CEMIP expression.
    Oncol Rep. 2019 Nov 8. doi: 10.3892/or.2019.7404.
    PubMed     Abstract available

    September 2019
  27. RAY J, Hoey C, Huang X, Jeon J, et al
    MicroRNA198 suppresses prostate tumorigenesis by targeting MIB1.
    Oncol Rep. 2019;42:1047-1056.
    PubMed     Abstract available

    July 2019
  28. TANG C, Liu T, Wang K, Wang X, et al
    Transcriptional regulation of FoxM1 by HIF1alpha mediates hypoxiainduced EMT in prostate cancer.
    Oncol Rep. 2019 Jul 25. doi: 10.3892/or.2019.7248.
    PubMed     Abstract available

  29. LING XH, Fu H, Chen ZY, Lu JM, et al
    miR505 suppresses prostate cancer progression by targeting NRCAM.
    Oncol Rep. 2019 Jul 11. doi: 10.3892/or.2019.7231.
    PubMed     Abstract available

  30. KAMINSKA K, Bialkowska A, Kowalewski J, Huang S, et al
    Differential gene methylation patterns in cancerous and noncancerous cells.
    Oncol Rep. 2019;42:43-54.
    PubMed     Abstract available

  31. MARTINS CA, Rocha GDG, Gattass CR, Takiya CM, et al
    Pomolic acid exhibits anticancer potential against a docetaxelresistant PC3 prostate cell line.
    Oncol Rep. 2019;42:328-338.
    PubMed     Abstract available

    May 2019
  32. MURAMATSU H, Sumitomo M, Morinaga S, Kajikawa K, et al
    Targeting lactate dehydrogenaseA promotes docetaxelinduced cytotoxicity predominantly in castrationresistant prostate cancer cells.
    Oncol Rep. 2019 May 24. doi: 10.3892/or.2019.7171.
    PubMed     Abstract available

  33. XU SG, Yu JJ, Shi Q, Niu Q, et al
    Conditionally replicative adenovirus carrying shRNA targeting EZH2 inhibits prostate cancer growth and invasion.
    Oncol Rep. 2019 May 13. doi: 10.3892/or.2019.7157.
    PubMed     Abstract available

    April 2019
  34. ZHANG J, Wang J, Luan T, Zuo Y, et al
    Deubiquitinase USP9X regulates the invasion of prostate cancer cells by regulating the ERK pathway and mitochondrial dynamics.
    Oncol Rep. 2019 Apr 18. doi: 10.3892/or.2019.7131.
    PubMed     Abstract available

    March 2019
  35. SUN W, Li L, Du Z, Quan Z, et al
    Combination of phospholipase Cepsilon knockdown with GANT61 sensitizes castrationresistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
    Oncol Rep. 2019 Mar 7. doi: 10.3892/or.2019.7054.
    PubMed     Abstract available

    January 2019
  36. ZHANG N, Su P, Li X, Xi J, et al
    Downregulated Kruppellike factor 4 expression is associated with the aggressiveness of prostate cancer.
    Oncol Rep. 2019 Jan 22. doi: 10.3892/or.2019.6975.
    PubMed     Abstract available

    December 2018
  37. LIAO W, Liu J, Liu B, Huang X, et al
    JIB04 induces cell apoptosis via activation of the p53/Bcl2/caspase pathway in MHCC97H and HepG2 cells.
    Oncol Rep. 2018;40:3812-3820.
    PubMed     Abstract available

    November 2018
  38. KAWAN MA, Kyrou I, Ramanjaneya M, Williams K, et al
    Involvement of the glutamine RFamide peptide and its cognate receptor GPR103 in prostate cancer.
    Oncol Rep. 2018 Nov 27. doi: 10.3892/or.2018.6893.
    PubMed     Abstract available

  39. YE J, Chu C, Chen M, Shi Z, et al
    TROAP regulates prostate cancer progression via the WNT3/survivin signalling pathways.
    Oncol Rep. 2018 Nov 9. doi: 10.3892/or.2018.6854.
    PubMed     Abstract available

  40. TAKAO A, Yoshikawa K, Karnan S, Ota A, et al
    Generation of PTENknockout (/) murine prostate cancer cells using the CRISPR/Cas9 system and comprehensive gene expression profiling.
    Oncol Rep. 2018;40:2455-2466.
    PubMed     Abstract available

  41. WU S, Huang J, Hui K, Yue Y, et al
    2'Hydroxyflavanone inhibits epithelialmesenchymal transition, and cell migration and invasion via suppression of the Wnt/betacatenin signaling pathway in prostate cancer.
    Oncol Rep. 2018;40:2836-2843.
    PubMed     Abstract available

    October 2018
  42. TANG Y, Wu B, Huang S, Peng X, et al
    Downregulation of miR5053p predicts poor bone metastasisfree survival in prostate cancer.
    Oncol Rep. 2018 Oct 25. doi: 10.3892/or.2018.6826.
    PubMed     Abstract available

  43. WANG H, Huang W, Yu X, Li W, et al
    Two prostate cancerassociated polymorphisms in the 3'UTR of IGF1R influences prostate cancer susceptibility by affecting miRNA binding.
    Oncol Rep. 2018 Oct 22. doi: 10.3892/or.2018.6810.
    PubMed     Abstract available

  44. NASSER MI, Han T, Adlat S, Tian Y, et al
    Inhibitory effects of Schisandrin B on human prostate cancer cells.
    Oncol Rep. 2018 Oct 15. doi: 10.3892/or.2018.6791.
    PubMed     Abstract available

  45. MITRAN B, Andersson KG, Lindstrom E, Garousi J, et al
    Affibodymediated imaging of EGFR expression in prostate cancer using radiocobaltlabeled DOTAZEGFR:2377.
    Oncol Rep. 2018 Oct 15. doi: 10.3892/or.2018.6792.
    PubMed     Abstract available

  46. GAN BL, Zhang LJ, Gao L, Ma FC, et al
    Downregulation of miR2245p in prostate cancer and its relevant molecular mechanism via TCGA, GEO database and in silico analyses.
    Oncol Rep. 2018 Oct 3. doi: 10.3892/or.2018.6766.
    PubMed     Abstract available

  47. ZHANG P, Li Y, Tang X, Guo R, et al
    Zinc enhances chemosensitivity to paclitaxel in PC3 prostate cancer cells.
    Oncol Rep. 2018;40:2269-2277.
    PubMed     Abstract available

  48. DONG Q, Lv C, Zhang G, Yu Z, et al
    Impact of RNAbinding motif 3 expression on the whole transcriptome of prostate cancer cells: An RNA sequencing study.
    Oncol Rep. 2018;40:2307-2315.
    PubMed     Abstract available

  49. ULLAH K, Addai Peprah F, Yu F, Shi H, et al
    The application of prostate specific membrane antigen in CARTcell therapy for treatment of prostate carcinoma (Review).
    Oncol Rep. 2018 Oct 1. doi: 10.3892/or.2018.6758.
    PubMed     Abstract available

    August 2018
  50. WANG J, Yang X, Li R, Wang L, et al
    Long non-coding RNA MYU promotes prostate cancer proliferation by mediating the miR-184/c-Myc axis.
    Oncol Rep. 2018 Aug 20. doi: 10.3892/or.2018.6661.
    PubMed     Abstract available

  51. DIAO X, Chen X, Pi Y, Zhang Y, et al
    Androgen receptor induces EPHA3 expression by interacting with transcription factor SP1.
    Oncol Rep. 2018;40:1174-1184.
    PubMed     Abstract available

    July 2018
  52. LIN JZ, Hameed I, Xu Z, Yu Y, et al
    Efficacy of gefitinibcelecoxib combination therapy in docetaxelresistant prostate cancer.
    Oncol Rep. 2018 Jul 24. doi: 10.3892/or.2018.6595.
    PubMed     Abstract available

    June 2018
  53. XU M, Jaing H, Wang H, Liu J, et al
    SB225002 inhibits prostate cancer invasion and attenuates the expression of BSP, OPN and MMP2.
    Oncol Rep. 2018 Jun 18. doi: 10.3892/or.2018.6504.
    PubMed     Abstract available

  54. KOU R, Zhao J, Gogoi P, Carskadon S, et al
    Enrichment and mutation detection of circulating tumor cells from blood samples.
    Oncol Rep. 2018;39:2537-2544.
    PubMed     Abstract available

    May 2018
  55. TANG Q, Ma J, Sun J, Yang L, et al
    Genistein and AG1024 synergistically increase the radiosensitivity of prostate cancer cells.
    Oncol Rep. 2018 May 30. doi: 10.3892/or.2018.6468.
    PubMed     Abstract available

    April 2018
  56. LIU Z, Zhang H, Ding S, Qi S, et al
    betaKlotho inhibits androgen/androgen receptorassociated epithelialmesenchymal transition in prostate cancer through inactivation of ERK1/2 signaling.
    Oncol Rep. 2018 Apr 25. doi: 10.3892/or.2018.6399.
    PubMed     Abstract available

  57. YANG A, Zhao Y, Wang Y, Zha X, et al
    Huaier suppresses proliferative and metastatic potential of prostate cancer PC3 cells via downregulation of Lamin B1 and induction of autophagy.
    Oncol Rep. 2018 Apr 5. doi: 10.3892/or.2018.6358.
    PubMed     Abstract available

    March 2018
  58. CHEN Q, Zhu L, Zong H, Song X, et al
    Subcellular localization of aquaporin 3 in prostate cancer is regulated by RalA.
    Oncol Rep. 2018 Mar 9. doi: 10.3892/or.2018.6308.
    PubMed     Abstract available

  59. XU S, Ge J, Zhang Z, Zhou W, et al
    miR-141 inhibits prostatic cancer cell proliferation and migration, and induces cell apoptosis via targeting of RUNX1.
    Oncol Rep. 2018;39:1454-1460.
    PubMed     Abstract available

    January 2018
  60. CAI C, He H, Duan X, Wu W, et al
    miR-195 inhibits cell proliferation and angiogenesis in human prostate cancer by downregulating PRR11 expression.
    Oncol Rep. 2018 Jan 31. doi: 10.3892/or.2018.6240.
    PubMed     Abstract available

  61. LAI Y, Kong Z, Zeng T, Xu S, et al
    PARP1-siRNA suppresses human prostate cancer cell growth and progression.
    Oncol Rep. 2018 Jan 26. doi: 10.3892/or.2018.6238.
    PubMed     Abstract available

    November 2017
  62. LIU T, Qiu X, Zhao X, Yang R, et al
    Hypermethylation of the SPARC promoter and its prognostic value for prostate cancer.
    Oncol Rep. 2017 Nov 29. doi: 10.3892/or.2017.6121.
    PubMed     Abstract available

  63. WA Q, Li L, Lin H, Peng X, et al
    Downregulation of miR19a3p promotes invasion, migration and bone metastasis via activating TGFbeta signaling in prostate cancer.
    Oncol Rep. 2017 Nov 13. doi: 10.3892/or.2017.6096.
    PubMed     Abstract available

  64. KUBO M, Satoh T, Ishiyama H, Tabata KI, et al
    Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy.
    Oncol Rep. 2017 Nov 13. doi: 10.3892/or.2017.6095.
    PubMed     Abstract available

  65. ZOU P, Yang Y, Xu X, Liu B, et al
    Silencing of vacuolar ATPase c subunit ATP6V0C inhibits the invasion of prostate cancer cells through a LASS2/TMSG1-independent manner.
    Oncol Rep. 2017 Nov 10. doi: 10.3892/or.2017.6092.
    PubMed     Abstract available

  66. SZYSZKA M, Tyczewska M, Milecka P, Jopek K, et al
    Effects of leptin on leptin receptor isoform expression and proliferative activity in human normal prostate and prostate cancer cell lines.
    Oncol Rep. 2017 Nov 1. doi: 10.3892/or.2017.6066.
    PubMed     Abstract available

    October 2017
  67. KOU B, Liu W, Zhao W, Duan P, et al
    Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-beta/Smad2/3 signaling pathway.
    Oncol Rep. 2017 Oct 2. doi: 10.3892/or.2017.6012.
    PubMed     Abstract available

    September 2017
    DNA methylation and histone modifications as epigenetic regulation in prostate cancer (Review).
    Oncol Rep. 2017 Sep 20. doi: 10.3892/or.2017.5972.
    PubMed     Abstract available

  69. ZHOU Y, Gu P, Li J, Li F, et al
    Suppression of STIM1 inhibits the migration and invasion of human prostate cancer cells and is associated with PI3K/Akt signaling inactivation.
    Oncol Rep. 2017 Sep 18. doi: 10.3892/or.2017.5961.
    PubMed     Abstract available

  70. LING Z, Liu D, Zhang G, Liang Q, et al
    miR-361-5p modulates metabolism and autophagy via the Sp1-mediated regulation of PKM2 in prostate cancer.
    Oncol Rep. 2017;38:1621-1628.
    PubMed     Abstract available

    August 2017
  71. KHURANA N, Kim H, Chandra PK, Talwar S, et al
    Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
    Oncol Rep. 2017 Aug 30. doi: 10.3892/or.2017.5932.
    PubMed     Abstract available

    July 2017
  72. GAO C, Zhou Y, Jiang Z, Zhao Y, et al
    Cytotoxic and chemosensitization effects of Scutellarin from traditional Chinese herb Scutellaria altissima L. in human prostate cancer cells.
    Oncol Rep. 2017 Jul 24. doi: 10.3892/or.2017.5850.
    PubMed     Abstract available

  73. ZHOU Y, Ji Z, Yan W, Zhou Z, et al
    The biological functions and mechanism of miR212 in prostate cancer proliferation, migration and invasion via targeting Engrailed-2.
    Oncol Rep. 2017 Jul 12. doi: 10.3892/or.2017.5805.
    PubMed     Abstract available

    June 2017
  74. ZHOU Y, Ji Z, Yan W, Zhou Z, et al
    Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1.
    Oncol Rep. 2017 Jun 29. doi: 10.3892/or.2017.5768.
    PubMed     Abstract available

  75. XUAN Q, Zhong X, Li W, Mo Z, et al
    CtBP2 is associated with angiogenesis and regulates the apoptosis of prostate cancer cells.
    Oncol Rep. 2017 Jun 28. doi: 10.3892/or.2017.5763.
    PubMed     Abstract available

    May 2017
  76. HATA S, Nomura T, Iwasaki K, Sato R, et al
    Hypoxia-induced angiopoietin-like protein 4 as a clinical biomarker and treatment target for human prostate cancer.
    Oncol Rep. 2017 May 24. doi: 10.3892/or.2017.5669.
    PubMed     Abstract available

  77. LIU L, Lou N, Li X, Xu G, et al
    Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
    Oncol Rep. 2017 May 4. doi: 10.3892/or.2017.5623.
    PubMed     Abstract available

  78. BAI S, Chen T, Yu X, Luo M, et al
    The specific killing effect of matrine on castration-resistant prostate cancer cells by targeting the Akt/FoxO3a signaling pathway.
    Oncol Rep. 2017;37:2819-2828.
    PubMed     Abstract available

    April 2017
  79. YIN B, Liu Z, Wang Y, Wang X, et al
    RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells.
    Oncol Rep. 2017 Apr 19. doi: 10.3892/or.2017.5585.
    PubMed     Abstract available

    March 2017
  80. ZHAO Y, Yan M, Yun Y, Zhang J, et al
    MicroRNA-455-3p functions as a tumor suppressor by targeting eIF4E in prostate cancer.
    Oncol Rep. 2017 Mar 13. doi: 10.3892/or.2017.5502.
    PubMed     Abstract available

  81. BAI Y, Xiao Y, Dai Y, Chen X, et al
    Stanniocalcin 1 promotes cell proliferation via cyclin E1/cyclindependent kinase 2 in human prostate carcinoma.
    Oncol Rep. 2017 Mar 13. doi: 10.3892/or.2017.5501.
    PubMed     Abstract available

  82. ZHANG H, Du X, Sun TT, Wang CL, et al
    Lectin PCL inhibits the Warburg effect of PC3 cells by combining with EGFR and inhibiting HK2.
    Oncol Rep. 2017;37:1765-1771.
    PubMed     Abstract available

    February 2017
  83. KONG Q, Chen XS, Tian T, Xia XY, et al
    MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein.
    Oncol Rep. 2017;37:803-812.
    PubMed     Abstract available

    January 2017
  84. SUN W, Guo L, Shao G, Liu X, et al
    Suppression of LASP-1 attenuates the carcinogenesis of prostatic cancer cell lines: Key role of the NF-kappaB pathway.
    Oncol Rep. 2017;37:341-347.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.